126 related articles for article (PubMed ID: 8911396)
1. Detection of c-erbB-2 amplification in transitional cell bladder carcinoma using competitive PCR technique.
Orlando C; Sestini R; Vona G; Pinzani P; Bianchi S; Giacca M; Pazzagli M; Selli C
J Urol; 1996 Dec; 156(6):2089-93. PubMed ID: 8911396
[TBL] [Abstract][Full Text] [Related]
2. C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors?
Underwood M; Bartlett J; Reeves J; Gardiner DS; Scott R; Cooke T
Cancer Res; 1995 Jun; 55(11):2422-30. PubMed ID: 7757996
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of amplification of c-erb-B2 in bladder carcinoma.
Lönn U; Lönn S; Friberg S; Nilsson B; Silfverswärd C; Stenkvist B
Clin Cancer Res; 1995 Oct; 1(10):1189-94. PubMed ID: 9815911
[TBL] [Abstract][Full Text] [Related]
4. Retrospective evaluation of c-erbB-2 oncogene amplification using competitive PCR in collecting duct carcinoma of the kidney.
Selli C; Amorosi A; Vona G; Sestini R; Travaglini F; Bartoletti R; Orlando C
J Urol; 1997 Jul; 158(1):245-7. PubMed ID: 9186368
[TBL] [Abstract][Full Text] [Related]
5. Prognostic role of the tumor-associated tissue inflammatory reaction in transitional bladder cell carcinoma.
Cai T; Nesi G; Boddi V; Mazzoli S; Dal Canto M; Bartoletti R
Oncol Rep; 2006 Aug; 16(2):329-34. PubMed ID: 16820911
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for primary superficial transitional cell carcinoma of the bladder: a retrospective cohort study.
Yang TB; Zeng FH; Sun ZQ
Chin Med J (Engl); 2006 Nov; 119(21):1821-8. PubMed ID: 17097038
[TBL] [Abstract][Full Text] [Related]
7. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?
Gandour-Edwards R; Lara PN; Folkins AK; LaSalle JM; Beckett L; Li Y; Meyers FJ; DeVere-White R
Cancer; 2002 Sep; 95(5):1009-15. PubMed ID: 12209684
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of static cytometry in transitional cell carcinoma of the bladder: recurrence rate and survival in a group of patients at 10 years follow-up.
Cai T; Margallo E; Nesi G; Giubilei G; Rizzo M; Bartoletti R
Oncol Rep; 2006 Jan; 15(1):213-9. PubMed ID: 16328058
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome.
Krüger S; Weitsch G; Büttner H; Matthiensen A; Böhmer T; Marquardt T; Sayk F; Feller AC; Böhle A
Int J Oncol; 2002 Nov; 21(5):981-7. PubMed ID: 12370744
[TBL] [Abstract][Full Text] [Related]
10. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17.
Simonetti S; Russo R; Ciancia G; Altieri V; De Rosa G; Insabato L
Int J Surg Pathol; 2009 Jun; 17(3):198-205. PubMed ID: 19443884
[TBL] [Abstract][Full Text] [Related]
11. Detection of C-erb B2 gene amplification in bilharzial associated bladder cancer using fluorescence in situ hybridization.
Aly MS; Khaled HM
Urol Oncol; 2004; 22(6):448-52. PubMed ID: 15610859
[TBL] [Abstract][Full Text] [Related]
12. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E
Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605
[TBL] [Abstract][Full Text] [Related]
13. Molecular and immunohistochemical evaluation of epidermal growth factor receptor and c-erb-B-2 gene product in transitional cell carcinomas of the urinary bladder: a study in Greek patients.
Gorgoulis VG; Barbatis C; Poulias I; Karameris AM
Mod Pathol; 1995 Sep; 8(7):758-64. PubMed ID: 8539234
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of DNA content in bladder cancer based on flow cytometric analysis of 249 transitional cell carcinomas.
Vindeløv LL; Christensen IJ; Engelholm SA; Guldhammer BH; Højgaard K; Sørensen BL; Wolf H
Cytometry; 1995 Jun; 22(2):93-102. PubMed ID: 7587754
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder.
Dekairelle AF; Tombal B; Cosyns JP; Gala JL
Clin Cancer Res; 2005 Jul; 11(13):4724-32. PubMed ID: 16000567
[TBL] [Abstract][Full Text] [Related]
16. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach.
Garcia del Muro X; Condom E; Vigués F; Castellsagué X; Figueras A; Muñoz J; Solá J; Soler T; Capellà G; Germà JR
Cancer; 2004 May; 100(9):1859-67. PubMed ID: 15112266
[TBL] [Abstract][Full Text] [Related]
17. Implications of p53 gene mutations on patient survival in transitional cell carcinoma of the bladder: a long-term study.
Salinas-Sánchez AS; Lorenzo-Romero JG; Giménez-Bachs JM; Sánchez-Sánchez F; Donate-Moreno MJ; Rubio-Del-Campo A; Hernández-Millán IR; Segura-Martín M; Atienzar-Tobarra M; Escribano-Martínez J
Urol Oncol; 2008; 26(6):620-6. PubMed ID: 18367096
[TBL] [Abstract][Full Text] [Related]
18. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
[TBL] [Abstract][Full Text] [Related]
19. [Expression of PCNA/cyclin, p53, C-erbB-2 versus histological grade in transitional cell carcinoma of urinary bladder].
Yoshikawa H; Ikeuchi T; Iguchi H; Onodera Y; Kai Y
Hinyokika Kiyo; 1995 Apr; 41(4):253-8. PubMed ID: 7785554
[TBL] [Abstract][Full Text] [Related]
20. [The molecular biology of bladder carcinoma].
Moreno Sierra J; Maestro de las Casas ML; Chicharro Almarza J; Ortega Heredia MD; López García-Asenjo J; Merino Sánchez C; Blanco Jiménez E; Silmi Moyano A; Rsesel Estévez L
Arch Esp Urol; 1997 Oct; 50(8):855-66. PubMed ID: 9463283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
